Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
PaperCitations, authors & open-access status
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 593 citations, 2017 year and closed oa status.
593
Citations
2017
Year
closed
OA Status